JPH0511264B2 - - Google Patents
Info
- Publication number
- JPH0511264B2 JPH0511264B2 JP59113226A JP11322684A JPH0511264B2 JP H0511264 B2 JPH0511264 B2 JP H0511264B2 JP 59113226 A JP59113226 A JP 59113226A JP 11322684 A JP11322684 A JP 11322684A JP H0511264 B2 JPH0511264 B2 JP H0511264B2
- Authority
- JP
- Japan
- Prior art keywords
- factor
- coagulation
- group
- reagent
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims description 41
- 230000015271 coagulation Effects 0.000 claims description 35
- 238000005345 coagulation Methods 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 230000000087 stabilizing effect Effects 0.000 claims description 20
- 239000003146 anticoagulant agent Substances 0.000 claims description 15
- 229940127219 anticoagulant drug Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 11
- 206010053567 Coagulopathies Diseases 0.000 claims description 10
- 230000035602 clotting Effects 0.000 claims description 10
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 9
- 239000003114 blood coagulation factor Substances 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 102000009123 Fibrin Human genes 0.000 claims description 8
- 108010073385 Fibrin Proteins 0.000 claims description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229950003499 fibrin Drugs 0.000 claims description 8
- -1 monosaccharide sugars Chemical class 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002897 heparin Drugs 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 125000001547 cellobiose group Chemical group 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 20
- 108090000783 Renin Proteins 0.000 description 12
- 102100028255 Renin Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 108010064733 Angiotensins Proteins 0.000 description 4
- 102000015427 Angiotensins Human genes 0.000 description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 108050006018 Coagulation factor VII Proteins 0.000 description 2
- 102100029117 Coagulation factor X Human genes 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 206010038464 renal hypertension Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XJFQCYIFOWHHFN-PLKCGDGVSA-N hypertensinogen Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 XJFQCYIFOWHHFN-PLKCGDGVSA-N 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50121683A | 1983-06-06 | 1983-06-06 | |
| US501216 | 1983-06-06 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP34986791A Division JPH0560753A (ja) | 1983-06-06 | 1991-12-10 | 血漿レニン対照試薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6018762A JPS6018762A (ja) | 1985-01-30 |
| JPH0511264B2 true JPH0511264B2 (fr) | 1993-02-15 |
Family
ID=23992589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11322684A Granted JPS6018762A (ja) | 1983-06-06 | 1984-06-04 | 安定化された凝固対照試薬 |
| JP34986791A Pending JPH0560753A (ja) | 1983-06-06 | 1991-12-10 | 血漿レニン対照試薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP34986791A Pending JPH0560753A (ja) | 1983-06-06 | 1991-12-10 | 血漿レニン対照試薬 |
Country Status (6)
| Country | Link |
|---|---|
| JP (2) | JPS6018762A (fr) |
| AU (1) | AU584859B2 (fr) |
| CA (1) | CA1226795A (fr) |
| DK (1) | DK275384A (fr) |
| IL (1) | IL72032A0 (fr) |
| NO (1) | NO842260L (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1226794A (fr) * | 1983-06-06 | 1987-09-15 | Michael K. Hoskins | Produit de controle stabilise multiparametre |
| US4663295A (en) * | 1983-06-29 | 1987-05-05 | Ciba Corning Diagnostics Corp. | Estrogen-progesterone control reagents and methods for making same |
| CA1230300A (fr) * | 1983-06-06 | 1987-12-15 | Michael K. Hoskins | Isoenzyme de controle stabilise |
| CA1226795A (fr) * | 1983-06-06 | 1987-09-15 | Michael K. Hoskins | Produits de controle stabilises de la coagulation |
| JPH0695092B2 (ja) * | 1989-10-30 | 1994-11-24 | 隆己 永田 | 血球計数用抗凝固剤 |
| WO2004046723A1 (fr) * | 2002-11-18 | 2004-06-03 | Denka Seiken Co., Ltd. | Methode de dosage immunologique supprimant les variations entre les donnees de mesure seriques et plasmatiques |
| US7588942B2 (en) * | 2006-08-04 | 2009-09-15 | Bio-Rad Laboratories, Inc. | Standard/reference/control for blood coagulation testing |
| JP5425062B2 (ja) * | 2009-03-05 | 2014-02-26 | 株式会社ビー・エム・エル | Ｄ−マンニトールを含有する管理試料を用いるグリコアルブミン等の測定方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5191310A (fr) * | 1974-12-31 | 1976-08-10 | ||
| JPS5757661A (en) * | 1980-09-25 | 1982-04-06 | Daicel Ltd | Film for separately packing sliced cheese |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1226794A (fr) * | 1983-06-06 | 1987-09-15 | Michael K. Hoskins | Produit de controle stabilise multiparametre |
| CA1230300A (fr) * | 1983-06-06 | 1987-12-15 | Michael K. Hoskins | Isoenzyme de controle stabilise |
| CA1226795A (fr) * | 1983-06-06 | 1987-09-15 | Michael K. Hoskins | Produits de controle stabilises de la coagulation |
| JPH0511264A (ja) * | 1991-07-05 | 1993-01-19 | Hitachi Ltd | 液晶表示装置 |
-
1984
- 1984-05-25 CA CA000455086A patent/CA1226795A/fr not_active Expired
- 1984-06-04 DK DK275384A patent/DK275384A/da not_active Application Discontinuation
- 1984-06-04 JP JP11322684A patent/JPS6018762A/ja active Granted
- 1984-06-05 AU AU29086/84A patent/AU584859B2/en not_active Ceased
- 1984-06-05 IL IL72032A patent/IL72032A0/xx unknown
- 1984-06-05 NO NO842260A patent/NO842260L/no unknown
-
1991
- 1991-12-10 JP JP34986791A patent/JPH0560753A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5191310A (fr) * | 1974-12-31 | 1976-08-10 | ||
| JPS5757661A (en) * | 1980-09-25 | 1982-04-06 | Daicel Ltd | Film for separately packing sliced cheese |
Also Published As
| Publication number | Publication date |
|---|---|
| DK275384A (da) | 1984-12-07 |
| AU2908684A (en) | 1984-12-13 |
| DK275384D0 (da) | 1984-06-04 |
| IL72032A0 (en) | 1984-10-31 |
| JPH0560753A (ja) | 1993-03-12 |
| JPS6018762A (ja) | 1985-01-30 |
| NO842260L (no) | 1984-12-07 |
| CA1226795A (fr) | 1987-09-15 |
| AU584859B2 (en) | 1989-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al-Mondhiry et al. | Fibrinogen"" New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation | |
| BAKER et al. | Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin: with autopsy findings of widespread intravascular clotting | |
| Rao et al. | Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. | |
| Quick et al. | The prothrombin consumption test: its clinical and theoretic implications | |
| Stefanini | Mechanism of blood coagulation in normal and pathologic conditions | |
| JPS58500994A (ja) | 止血用医薬組成物 | |
| GLUECK et al. | Myocardial infarction in a patient with a Hageman (factor XII) defect | |
| Ratnoff | Hemostatic mechanisms in liver disease | |
| JPH0511264B2 (fr) | ||
| CN109082458B (zh) | 一种血栓弹力图法定量检测口服凝血因子Xa抑制剂试剂盒及其制备方法 | |
| Fruchtman et al. | Disseminated intravascular coagulation | |
| DIDISHEIM | Hageman factor deficiency (Hageman trait): case report and review of the literature | |
| Ambrus et al. | Inhibitors of fibrinolysis in diabetic children, mothers, and their newborn | |
| Ries | Molecular and functional properties of fetal plasminogen and its possible influence on clot lysis in the neonatal period | |
| Flute | Coagulation and fibrinolysis after injury. | |
| Heikinheimo | Coagulation studies with fetal blood | |
| Amris et al. | Infusion of porcine plasmin in man. Studies on toxicology and pharmacodynamics | |
| Trusen et al. | Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA) | |
| Connor et al. | A labile serum factor clotting defect: its demonstration by the thromboplastin generation test and its clinical significance | |
| Angelos et al. | Coagulation studies: prothrombin time, partial thromboplastin time, bleeding time | |
| Merskey | DIC: Identification and management | |
| Davey et al. | Gamma globulin inhibition of fibrin clot formation | |
| Bick | Hereditary plasma protein disorders | |
| Quick | Hemolysate prothrombin consumption time: A new test for thromboplastinogenic coagulation defects | |
| Prentice et al. | Plasminogen activation and the coagulation process. |